Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab Monotherapy in Moderate-to-severe Atopic Dermatitis
NCT06130566Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: Validated Investigator Global Assessment scale for Atopic Dermatitis of 0 or 1 at 24 weeks and Eczema Area and Severity Index 75% reduction at 24 weeks. Started Nov 2023; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06130566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06130566.